What are the indications, dosing regimen, contraindications, adverse effects, and monitoring recommendations for felodipine?

Felodipine: Clinical Overview

Felodipine is a highly vascular-selective dihydropyridine calcium channel blocker indicated for hypertension treatment, dosed at 2.5-10 mg once daily, with the primary limitation being dose-related peripheral edema that increases with age.

Indications

Felodipine extended-release is FDA-approved specifically for hypertension management to lower blood pressure and reduce cardiovascular events including stroke and myocardial infarction 1. The drug may be used as monotherapy or combined with other antihypertensive agents 2, 3.

Key clinical contexts:

• Primary use: Essential hypertension at all severity levels 4
• Combination therapy: Particularly effective when combined with thiazide diuretics or ACE inhibitors/ARBs 5, 2
• Special populations: Elderly patients with isolated systolic hypertension 2, 6
• Angina pectoris: May be used for ongoing ischemic symptoms in patients already on nitrates and beta-blockers, though evidence is limited to symptom control 7, 8, 7

Important caveat: Felodipine is reasonably well tolerated in patients with mild left ventricular dysfunction, but avoid in patients with heart failure with reduced ejection fraction (HFrEF) unless amlodipine or felodipine specifically required 2, 3.

Dosing Regimen

Starting dose: 2.5-5 mg once daily 2, 3, 2

• Use 2.5 mg in elderly patients, those with hepatic impairment, or patients prone to hypotension 1

Maintenance dose: 5-10 mg once daily 2, 7

Maximum dose: 10 mg once daily 2, 3

• While 20 mg has been studied, there is a disproportionate increase in adverse events (especially vasodilatory effects like edema) without proportional BP benefit 1

Administration specifics:

• Take tablets whole; do not crush or chew 1
• Once-daily dosing provides 24-hour BP control 9
• May be taken without regard to meals, though grapefruit juice must be avoided 1

Contraindications

Absolute contraindications:

• Pregnancy (may cause fetal harm) 2, 3, 1
• Known hypersensitivity to felodipine or other dihydropyridines

Relative contraindications/strong cautions:

• Severe heart failure or pulmonary edema - avoid unless specifically indicated 7, 8, 7
• Severe hepatic impairment - requires dose reduction to 2.5 mg starting dose due to elevated plasma concentrations 1
• Severe hypotension - may precipitate significant hypotension or syncope 1
• Acute myocardial infarction - immediate-release dihydropyridines should be avoided; extended-release formulations require caution

Adverse Effects

Most common (dose and age-dependent):

Peripheral edema - the most frequent adverse effect 1

• Incidence: 10% in patients <50 years on 5 mg daily, up to 30% in patients >60 years on 20 mg daily
• Mechanism: Precapillary vasodilation, NOT fluid retention
• Onset: Typically within 2-3 weeks of initiation
• Management: Often necessitates discontinuation (~3% of patients) 1

Headache - 10-15% of patients 1

• Usually occurs early in treatment
• Often diminishes with continued therapy

Vasodilatory effects:

• Flushing: 4-7% 1
• Dizziness: 3-4% 1
• Palpitations: 1-3% 1
• Reflex tachycardia (may precipitate angina in susceptible patients) 1

Less common but notable:

• Gingival hyperplasia - occurs in <0.5% of patients; improved dental hygiene decreases incidence and severity 1
• Hypotension (may be significant) 1
• Nausea, dyspepsia, constipation: 1-2% 1

Serious but rare:

• Angioedema 1
• Syncope 1
• Leukocytoclastic vasculitis 1

Important pattern: Adverse effects are typically mild, transient, and related to vasodilation. They usually occur within the first 2 weeks and diminish with continued use 4, 10.

Drug Interactions

Critical CYP3A4 interactions - Felodipine is extensively metabolized by CYP3A4 1:

Strong CYP3A4 inhibitors (avoid or use extreme caution):

• Itraconazole: 8-fold increase in AUC, 6-fold increase in Cmax 1
• Erythromycin: 2.5-fold increase in AUC and Cmax 1
• Grapefruit juice: >2-fold increase in AUC and Cmax 1
• Cimetidine: ~50% increase in AUC and Cmax 1

CYP3A4 inducers:

• Anticonvulsants (phenytoin, carbamazepine, phenobarbital): Reduce felodipine levels to ~6% of normal - consider alternative antihypertensive therapy 1

Other significant interactions:

• Beta-blockers: Generally well tolerated; metoprolol levels may increase 31-38% 1
• Tacrolimus: Felodipine may increase tacrolimus blood levels - monitor closely 1
• Digoxin: No significant interaction 1

Monitoring Recommendations

Blood pressure monitoring:

• Check BP at trough (before next dose) to assess 24-hour control
• Target: <130/80 mmHg in most patients 2, 11
• Individualize for elderly based on frailty 12
• Achieve target within 3 months 12

Clinical monitoring:

• Peripheral edema: Assess at each visit, particularly in first 2-3 weeks
• Heart rate: Monitor for reflex tachycardia
• Symptoms of hypotension: Dizziness, syncope, especially in elderly

Laboratory monitoring:

• No routine laboratory monitoring required
• Consider renal function if used with ACE inhibitors/ARBs in combination therapy

Special population monitoring:

• Hepatic impairment: Close BP monitoring during dose adjustment 1
• Elderly patients: More frequent assessment for orthostatic hypotension and edema

Dental hygiene: Counsel patients on good oral hygiene to prevent/minimize gingival hyperplasia 1.

Common pitfall: The FEVER trial demonstrated that even small BP differences (4/2 mmHg) with felodipine addition to hydrochlorothiazide resulted in 27% stroke reduction 13. Don't dismiss modest BP reductions as clinically insignificant - they translate to substantial cardiovascular benefit, particularly for stroke prevention.